Head to Head Survey: IDEXX Laboratories (IDXX) & Response Genetics (RGDXQ)

IDEXX Laboratories (NASDAQ:IDXX) and Response Genetics (OTCMKTS:RGDXQ) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Valuation & Earnings

This table compares IDEXX Laboratories and Response Genetics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IDEXX Laboratories $1.97 billion 8.50 $263.14 million $3.28 59.18
Response Genetics N/A N/A N/A N/A N/A

IDEXX Laboratories has higher revenue and earnings than Response Genetics.

Analyst Recommendations

This is a breakdown of current recommendations for IDEXX Laboratories and Response Genetics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEXX Laboratories 1 0 5 0 2.67
Response Genetics 0 0 0 0 N/A

IDEXX Laboratories presently has a consensus price target of $248.00, suggesting a potential upside of 28.20%. Given IDEXX Laboratories’ higher probable upside, research analysts plainly believe IDEXX Laboratories is more favorable than Response Genetics.

Risk & Volatility

IDEXX Laboratories has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Response Genetics has a beta of -0.61, meaning that its share price is 161% less volatile than the S&P 500.


This table compares IDEXX Laboratories and Response Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IDEXX Laboratories 15.19% -994.76% 23.09%
Response Genetics N/A N/A N/A

Insider and Institutional Ownership

91.7% of IDEXX Laboratories shares are owned by institutional investors. 2.6% of IDEXX Laboratories shares are owned by insiders. Comparatively, 4.9% of Response Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


IDEXX Laboratories beats Response Genetics on 7 of the 9 factors compared between the two stocks.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

Response Genetics Company Profile

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply